Vanguard Global Advisers
ZBIO

Vanguard Global Advisers’s Zenas BioPharma ZBIO Stock Holding History

Vanguard Global Advisers’s Portfolio ZBIO Stock Details ZBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$389K Sell
15,332
-5,508
-26% -$109K ﹤0.01% 2212
2026
Q1 		$407K Buy
+20,840
New +$468K ﹤0.01% 2135

Other funds holding ZBIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Global Advisers's ZBIO Position: Q2 2026 in Review

Vanguard Global Advisers reduced its Zenas BioPharma (ZBIO) stake by 26% in Q2 2026, selling an estimated $109K and leaving 15,332 shares worth $389K. The position accounts for ﹤0.01% of the portfolio, ranked #2212.

Vanguard Global Advisers first reported a position in ZBIO in Q1 2026 and has held it in 2 quarters since. The position peaked at $407K in Q1 2026. 144 funds tracked by Wall St. Rank hold ZBIO as of Q2 2026.

  • Vanguard Global Advisers held 15,332 shares of Zenas BioPharma worth $389K as of Q2 2026.
  • Vanguard Global Advisers sold 5,508 Zenas BioPharma shares in Q2 2026, an estimated $109K.
  • Zenas BioPharma made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q2 2026, its #2212 holding.
  • Vanguard Global Advisers first reported a position in Zenas BioPharma in Q1 2026 and has held it in 2 quarters since.
  • Vanguard Global Advisers's Zenas BioPharma position peaked at $407K in Q1 2026.
  • 144 funds tracked by Wall St. Rank held Zenas BioPharma as of Q2 2026.

Based on Vanguard Global Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.